Selpercatinib for carcinoma, medullary

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 26 Dec 2019: Trial registered, NCT04211337
  2. 11 Feb 2020: Trial started, NCT04211337

The trials

NCT03157128: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

State
Under way
Phase
Phase 1 and Phase 2
People
857 taking part
Started
2 May 2017
Primary completion
14 Feb 2025
Arms
Phase 1: 20 mg Selpercatinib QD, Phase 1: 20 mg Selpercatinib BID, Phase 1: 40 mg Selpercatinib BID, Phase 1: 60 mg Selpercatinib BID, Phase 1: 160 mg Selpercatinib QD, Phase 1: 80 mg Selpercatinib BID, Phase 1: 120 mg Selpercatinib BID, Phase 1: 160 mg Selpercatinib BID, Phase 1: 200 mg Selpercatinib BID, Phase 1: 240 mg Selpercatinib BID, Phase 2, Cohort 1: RET Fusion Solid Tumor, Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy, Phase 2, Cohort 3: RET Mutant MTC, Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy, Phase 2, Cohort 5: Advanced RET Altered Solid Tumor, Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
Results
Posted on the registry
  1. 2 May 2017: Trial started
  2. 17 May 2017: Trial registered
  3. 16 Apr 2026: Trial results posted

NCT04211337: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

State
Under way
Phase
Phase 3
People
291 taking part
Started
11 Feb 2020
Primary completion
22 May 2023
Arms
Selpercatinib - Treatment A (TRT A)
Results
Posted on the registry
  1. 26 Dec 2019: Trial registered
  2. 11 Feb 2020: Trial started
  3. 13 Jun 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Retevmo.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.